Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CRL 
Charles River Laboratories (CRL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CRL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $172.07
1 Year Target Price $172.07
| 4 | Strong Buy |
| 0 | Buy |
| 14 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -15.47% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.03B USD | Price to earnings Ratio - | 1Y Target Price 172.07 |
Price to earnings Ratio - | 1Y Target Price 172.07 | ||
Volume (30-day avg) 19 | Beta 1.48 | 52 Weeks Range 91.86 - 230.02 | Updated Date 08/28/2025 |
52 Weeks Range 91.86 - 230.02 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.31 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate 2.5 | Actual 3.12 |
Profitability
Profit Margin -1.66% | Operating Margin (TTM) 16.67% |
Management Effectiveness
Return on Assets (TTM) 4.31% | Return on Equity (TTM) -1.81% |
Valuation
Trailing PE - | Forward PE 17.09 | Enterprise Value 10635952133 | Price to Sales(TTM) 1.99 |
Enterprise Value 10635952133 | Price to Sales(TTM) 1.99 | ||
Enterprise Value to Revenue 2.64 | Enterprise Value to EBITDA 20.13 | Shares Outstanding 49214200 | Shares Floating 48623116 |
Shares Outstanding 49214200 | Shares Floating 48623116 | ||
Percent Insiders 1 | Percent Institutions 105.8 |
Upturn AI SWOT
Charles River Laboratories
Company Overview
History and Background
Founded in 1947 as Charles River Breeding Laboratories, it initially focused on providing lab animals. Over time, it expanded into a leading provider of drug discovery, preclinical and clinical laboratory services.
Core Business Areas
- Research Models and Services (RMS): Provides research models and services, including genetically engineered models, for preclinical research and drug discovery. This is where they began.
- Discovery and Safety Assessment (DSA): Offers drug discovery and safety assessment services, including pharmacology, toxicology, and bioanalysis, supporting early-stage drug development.
- Manufacturing Solutions (Manufacturing): Manufactures biologic products for cell and gene therapies under CDMO programs and is an area of recent focus for the company to diversify.
Leadership and Structure
James C. Foster is the Chairman, President, and CEO. The company has a typical corporate structure with executive leadership overseeing various business units.
Top Products and Market Share
Key Offerings
- Research Models: Specifically, genetically engineered mice and rats. Market share is estimated at around 40% in this segment. Competitors include Envigo (now Inotiv) and Taconic Biosciences. Revenue is tied to preclinical research budgets.
- Preclinical Services: Toxicology and safety testing services for pharmaceuticals and biotech. Market share estimated at 15-20% in the outsourced segment. Competitors include WuXi AppTec and Labcorp Drug Development. Revenue tied to the volume of outsourced preclinical work by pharma.
- Cell and Gene Therapy Manufacturing: Manufacturing of biologic products for the pharmaceutical and biotech industry. A small but rapidly growing segment and one that CRL wants to expand in. Competitors here are much larger, but more diverse like Thermo Fisher and Danaher.
Market Dynamics
Industry Overview
The industry includes contract research organizations (CROs), laboratory animal suppliers, and CDMOs. Growth is driven by pharmaceutical R&D spending, increased outsourcing, and advancements in cell and gene therapy.
Positioning
Charles River Laboratories is a leader in preclinical services and research models, benefiting from its broad portfolio and established reputation. They have a competitive advantage in the scale of their operations and their ability to offer integrated services.
Total Addressable Market (TAM)
The total addressable market is estimated at over $80 billion. Charles River Laboratories captures a portion of this, with opportunities for further expansion in the preclinical services and cell & gene therapy segments.
Upturn SWOT Analysis
Strengths
- Broad service portfolio
- Global presence
- Established reputation
- Strong relationships with pharmaceutical companies
- Scale of operations
Weaknesses
- High dependence on pharmaceutical R&D spending
- Integration challenges with acquisitions
- Exposure to animal rights activism
- Regulatory scrutiny
Opportunities
- Growth in cell and gene therapy market
- Increased outsourcing of preclinical services
- Expansion into emerging markets
- Development of innovative research models and technologies
Threats
- Economic downturn impacting pharmaceutical R&D budgets
- Increased competition from CROs
- Changes in regulations governing animal research
- Patent expirations on key products
Competitors and Market Share
Key Competitors
- WuXi AppTec (2359.HK)
- Labcorp (LH)
- Thermo Fisher Scientific (TMO)
- Danaher (DHR)
Competitive Landscape
Charles River Laboratories excels in preclinical services and research models. However, companies like Thermo Fisher have a broader life sciences portfolio. WuXi AppTec offers a full suite of services but lacks the focused expertise of CRL in certain areas.
Major Acquisitions
Cognex Corporationu2019s In-Vitro ADMET Business
- Year: 2021
- Acquisition Price (USD millions): 87
- Strategic Rationale: Expands capabilities in in vitro ADMET (absorption, distribution, metabolism, excretion, and toxicity) testing.
Vivotecnica
- Year: 2022
- Acquisition Price (USD millions): 143
- Strategic Rationale: European contract research organization (CRO) specializing in preclinical services.
Growth Trajectory and Initiatives
Historical Growth: Charles River Laboratories has grown through organic expansion and strategic acquisitions.
Future Projections: Analysts project continued growth in revenue, driven by demand for preclinical services and growth in emerging markets. However, profit margins might face pressure due to increased competition and R&D investments.
Recent Initiatives: Recent initiatives include expanding its cell and gene therapy manufacturing capabilities and investing in new technologies for drug discovery.
Summary
Charles River Laboratories is a significant player in preclinical and research services, benefiting from its scale and reputation. The company has demonstrated solid historical growth but faces challenges with profit margins and increased competition. Investments in cell and gene therapy offer promising avenues for future growth. The stock has potential but the short-term impact of economic cycles may impact the share price.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (10K, 10Q), Investor Presentations, Analyst Reports, Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is based on estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Charles River Laboratories
Exchange NYSE | Headquaters Wilmington, MA, United States | ||
IPO Launch date 2000-06-23 | Chairman, President & CEO Mr. James C. Foster J.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 18700 | Website https://www.criver.com |
Full time employees 18700 | Website https://www.criver.com | ||
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It utilizes Logica, a platform offering from Valo Health, to identify advanceable small molecule leads. It provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.